Biomarin Pharmaceutical (BMRN) Equity Ratio (2009 - 2026)

Biomarin Pharmaceutical has disclosed Equity Ratio across 18 years of filings, most recently posting 0.72 for Q1 2026.

• Quarterly Equity Ratio fell 10.8% year-over-year to 0.72 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.72 (down 10.8% YoY) and the FY2025 annual result came in at 0.8, down 0.99% from the prior year.
• Equity Ratio slipped to 0.72 in Q1 2026, from 0.8 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.81 in Q1 2025 and troughed at 0.72 in Q4 2022.
• A 5-year average of 0.75 and a median of 0.73 in 2022 frame the typical range for Equity Ratio.
• Annual changes were most pronounced in 2024 — Equity Ratio rose 11.86% — and 2026, when it decreased 10.8%.
• Tracing BMRN's Equity Ratio over 5 years: stood at 0.72 in 2022, then climbed by 0.23% to 0.72 in 2023, then increased by 11.86% to 0.81 in 2024, then dropped by 0.99% to 0.8 in 2025, then decreased by 9.79% to 0.72 in 2026.
• Business Quant data shows BMRN's Equity Ratio at 0.72 in Q1 2026, 0.8 in Q4 2025, and 0.8 in Q3 2025.